Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00081627 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial in Patients With Metastatic Colorectal Cancer
A Phase 2 study of Colon Cancer and Rectal Cancer, sponsored by Mast Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 9
- Study locations
NCT00081627 is a Phase 2 study of Colon Cancer and Rectal Cancer that has completed, run by Mast Therapeutics. The registered enrollment target is 48 participants, below the 4,456-participant average among 97 other Colon Cancer trials with a reported enrollment target (99% lower). The trial reports 9 study locations across 4 states.
The verdict
NCT00081627, a Phase 2 study of Colon Cancer and Rectal Cancer, has completed, sponsored by Mast Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 9
- Study locations
Study Summary
The objectives of this trial are to determine if CoFactor in combination with 5-FU are effective in the treatment of metastatic colorectal cancer and to determine the side effects observed with the administration of CoFactor and 5-FU.
Conditions Studied
Interventions
- DRUG CoFactor and 5FU
Study Locations (9)
Other
- CHC Bezanijska Kosa - Belgrade
- Clinical Center of Serbia - Belgrade
- Institute for Oncology and Radiology Serbia - Belgrade
- Institute of Oncology - Sremska Kamenica
California
- UCSD Moores Cancer Center - La Jolla
- Mercy General Hospital - Sacramento
- VA San Diego Healthcare System - San Diego
Michigan
- Spectrum Health - Grand Rapids
Texas
- Killeen Cancer Center - Killeen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2004-04 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00081627
The ClinicalTrials.gov registry entry for NCT00081627 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,456-participant average among 97 other Colon Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Mast Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Colon Cancer appearing as the primary indexed condition, and to 1 intervention - of which CoFactor and 5FU is the first listed.
NCT00081627 reports 9 study locations spanning 4 distinct geographic areas - top geographies include Other, California, Michigan.
Frequently Asked Questions
What is clinical trial NCT00081627 about?
NCT00081627 is a clinical study titled "Clinical Trial in Patients With Metastatic Colorectal Cancer". The objectives of this trial are to determine if CoFactor in combination with 5-FU are effective in the treatment of metastatic colorectal cancer and to determine the side effects observed with the administration of CoFactor and 5-FU.
What is the current status of trial NCT00081627?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2004-04. Estimated completion is 2007-01.
What conditions does trial NCT00081627 study?
This clinical trial studies the following conditions: Colon Cancer, Rectal Cancer.
What interventions are being tested in trial NCT00081627?
The interventions under investigation include: CoFactor and 5FU (DRUG).
Who is sponsoring clinical trial NCT00081627?
This trial is sponsored by Mast Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00081627 being conducted?
This trial has 9 study locations across California, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colon Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
RECRUITING · Phase 2
-
Phase II Trial of Lung Chemoemobolization
RECRUITING · Phase 2
-
Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
RECRUITING · Phase 2
-
Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers
RECRUITING · Phase 2
-
The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer
RECRUITING · Phase 2
-
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.